Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...
Medpage Today on MSN
Two Treatments Show Benefits in Juvenile Myasthenia Gravis
SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.
Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia gravis, but long-term results will be key.
Data Safety Monitoring Committee (DSMC): The company announced completion of the fourth and final scheduled safety review by the DSMC for the ORCA-OL trial. Adverse events were mostly mild in severity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback